Potential repositioning of GV1001 as a therapeutic agent for testosterone‑induced benign prostatic hyperplasia

International Journal of Molecular Medicine
Kyeong Seok KimHyung Sik Kim

Abstract

Benign prostatic hyperplasia (BPH) is one of the leading causes of male reproductive disorders. Therapeutic agents currently in use have severe side effects; therefore, alternative drugs that exhibit improved therapeutic activity without side effects are required. The present study investigated the protective effect of GV1001 against testosterone‑induced BPH in rats. BPH in castrated rats was established via daily subcutaneous (s.c.) injections of testosterone propionate (TP, 3 mg/kg) dissolved in corn oil for 4 weeks. GV1001 (0.01, 0.1 and 1 mg/kg, s.c.) was administered 3 times per week for 4 weeks, together with TP (3 mg/kg) injection. The rats were sacrificed on the last day of treatment, and their prostates were excised and weighed for biochemical and histological studies. Serum levels of testosterone and dihydrotestosterone (DHT) were also measured. In rats with TP‑induced BPH, a significant increase in prostate weight (PW) and prostatic index (PI), accompanied by a decrease in antioxidant enzyme activity, was observed. Histological studies revealed clearly enlarged glandular cavities in rats with BPH. GV1001 (0.01 and 0.1 mg/kg) treatment significantly decreased PW and PI in rats with TP‑induced BPH. In addition, GV1001 ...Continue Reading

References

Jun 8, 2001·Human Reproduction Update·C SultanJ C Nicolas
Dec 26, 2001·Urology·S J JacobsenM M Lieber
Dec 26, 2001·Urology·W D Steers
Mar 27, 2003·Urology·Culley Carson, Roger Rittmaster
Apr 25, 2003·Lancet·A Thorpe, D Neal
Aug 23, 2005·Cancer Letters·Imtiaz A SiddiquiYogeshwer Shukla
Jul 21, 2006·Asian Journal of Andrology·Sahdeo PrasadYogeshwer Shukla
Sep 9, 2006·BMJ : British Medical Journal·Anand K Patel, Christopher R Chapple
Dec 17, 2008·Expert Review of Gastroenterology & Hepatology·Gary MiddletonJohn P Neoptolemos
Apr 25, 2009·Expert Opinion on Investigational Drugs·Jon Amund Kyte
Jun 18, 2011·Cancer Immunology, Immunotherapy : CII·Robert E HungerGustav Gaudernack
Sep 16, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Paal Fr BrunsvigSteinar Aamdal
Jul 1, 2005·Indian Journal of Clinical Biochemistry : IJCB·D S L Srivastava, R D Mittal
Nov 20, 2012·Current Opinion in Urology·Yakup BostanciBob Djavan
Dec 17, 2014·Urologia Internationalis·Paola Lucia MinciulloSebastiano Gangemi
Aug 25, 2015·Reviews in Endocrine & Metabolic Disorders·Abdulmaged M TraishMichael Zitzmann
May 6, 2016·Nature Reviews. Disease Primers·Bilal ChughtaiSteven A Kaplan
May 29, 2016·Journal of Ethnopharmacology·Ashish Kumar JenaManinder Karan
Nov 17, 2016·Investigative and Clinical Urology·Young Ju LeeHwancheol Son
May 26, 2017·Translational Andrology and Urology·Jason GandhiSardar Ali Khan
Aug 11, 2017·The Prostate·Gervaise HenryDouglas Strand

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.